CN105018524A - 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 - Google Patents
一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 Download PDFInfo
- Publication number
- CN105018524A CN105018524A CN201510405012.7A CN201510405012A CN105018524A CN 105018524 A CN105018524 A CN 105018524A CN 201510405012 A CN201510405012 A CN 201510405012A CN 105018524 A CN105018524 A CN 105018524A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- hbmsc
- angl
- star
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 130
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000033115 angiogenesis Effects 0.000 title abstract description 5
- 230000002035 prolonged effect Effects 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract description 66
- 238000001890 transfection Methods 0.000 claims abstract description 59
- 241000700605 Viruses Species 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 230000019491 signal transduction Effects 0.000 claims abstract description 15
- 210000001550 testis Anatomy 0.000 claims abstract description 15
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 claims description 71
- 239000013598 vector Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 108010017842 Telomerase Proteins 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 14
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000001413 cellular effect Effects 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 10
- 230000003511 endothelial effect Effects 0.000 claims description 9
- 239000012124 Opti-MEM Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 108091035539 telomere Proteins 0.000 claims description 7
- 102000055501 telomere Human genes 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 239000013613 expression plasmid Substances 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 210000003411 telomere Anatomy 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 230000005740 tumor formation Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 4
- 239000012097 Lipofectamine 2000 Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 102000057593 human F8 Human genes 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000012797 qualification Methods 0.000 claims description 4
- 229940047431 recombinate Drugs 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 210000004691 chief cell of stomach Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 210000001113 umbilicus Anatomy 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000012410 DNA Ligases Human genes 0.000 claims description 2
- 108010061982 DNA Ligases Proteins 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000702463 Geminiviridae Species 0.000 claims description 2
- 238000009004 PCR Kit Methods 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 239000011550 stock solution Substances 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 210000005239 tubule Anatomy 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 9
- 230000003213 activating effect Effects 0.000 abstract description 3
- 229920002477 rna polymer Polymers 0.000 abstract 2
- 208000005623 Carcinogenesis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108010072788 angiogenin Proteins 0.000 abstract 1
- 230000036952 cancer formation Effects 0.000 abstract 1
- 231100000504 carcinogenesis Toxicity 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 101001050607 Homo sapiens KH domain-containing, RNA-binding, signal transduction-associated protein 3 Proteins 0.000 description 51
- 102100023428 KH domain-containing, RNA-binding, signal transduction-associated protein 3 Human genes 0.000 description 51
- 238000011580 nude mouse model Methods 0.000 description 9
- 238000010254 subcutaneous injection Methods 0.000 description 9
- 239000007929 subcutaneous injection Substances 0.000 description 9
- 210000004504 adult stem cell Anatomy 0.000 description 6
- 238000012637 gene transfection Methods 0.000 description 6
- 238000011031 large-scale manufacturing process Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 230000004862 vasculogenesis Effects 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000009441 vascular protection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510405012.7A CN105018524B (zh) | 2015-07-13 | 2015-07-13 | 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510405012.7A CN105018524B (zh) | 2015-07-13 | 2015-07-13 | 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105018524A true CN105018524A (zh) | 2015-11-04 |
CN105018524B CN105018524B (zh) | 2020-03-27 |
Family
ID=54408825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510405012.7A Active CN105018524B (zh) | 2015-07-13 | 2015-07-13 | 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105018524B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107177633A (zh) * | 2017-06-01 | 2017-09-19 | 深圳市疾病预防控制中心 | 促进StAR基因表达的表达载体及其构建方法和应用 |
CN110643571A (zh) * | 2019-10-22 | 2020-01-03 | 康妍葆(北京)干细胞科技有限公司 | 人角蛋白6a在干细胞培养中的应用及产品 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1860186B1 (en) * | 2003-03-10 | 2010-11-17 | Japan Science And Technology Agency | Method for distinguishing mesenchymal stem cells using different markers |
-
2015
- 2015-07-13 CN CN201510405012.7A patent/CN105018524B/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107177633A (zh) * | 2017-06-01 | 2017-09-19 | 深圳市疾病预防控制中心 | 促进StAR基因表达的表达载体及其构建方法和应用 |
CN107177633B (zh) * | 2017-06-01 | 2020-10-27 | 深圳市疾病预防控制中心 | 促进StAR基因表达的表达载体及其构建方法和应用 |
CN110643571A (zh) * | 2019-10-22 | 2020-01-03 | 康妍葆(北京)干细胞科技有限公司 | 人角蛋白6a在干细胞培养中的应用及产品 |
CN110643571B (zh) * | 2019-10-22 | 2021-07-27 | 康妍葆(北京)干细胞科技有限公司 | 人角蛋白6a在干细胞培养中的应用及产品 |
Also Published As
Publication number | Publication date |
---|---|
CN105018524B (zh) | 2020-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6797221B2 (ja) | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 | |
Mazurier et al. | Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment | |
Motono et al. | Production of transgenic chickens from purified primordial germ cells infected with a lentiviral vector | |
Mao et al. | MicroRNA-23a is involved in tumor necrosis factor-α induced apoptosis in mesenchymal stem cells and myocardial infarction | |
Paul et al. | Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction | |
JP6868565B2 (ja) | 不死化幹細胞、及びその作製方法 | |
Lan et al. | Safe genetic modification of cardiac stem cells using a site-specific integration technique | |
CN102438631A (zh) | 抗hiv干细胞及其用途 | |
Li et al. | Integrin β1 increases stem cell survival and cardiac function after myocardial infarction | |
Lepperhof et al. | Bioluminescent imaging of genetically selected induced pluripotent stem cell-derived cardiomyocytes after transplantation into infarcted heart of syngeneic recipients | |
CN113278591B (zh) | 一种心脏靶向性基因工程外泌体及其制备方法和应用 | |
Pajarinen et al. | Establishment of green fluorescent protein and firefly luciferase expressing mouse primary macrophages for in vivo bioluminescence imaging | |
JP6750782B2 (ja) | 移植用幹細胞及びその製造方法 | |
Zhou et al. | Angiogenic gene‐modified myoblasts promote vascularization during repair of skeletal muscle defects | |
US20140065110A1 (en) | Genetically modified msc and therapeutic methods | |
CN111944748A (zh) | 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体及其用途 | |
Alaee et al. | Biodistribution of LV-TSTA transduced rat bone marrow cells used for “ex-vivo” regional gene therapy for bone repair | |
CN105018524A (zh) | 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒 | |
CN108883136A (zh) | Vcn增强子组合物及其使用方法 | |
KR102673203B1 (ko) | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 | |
CN109593725A (zh) | 一种重组间充质干细胞及其应用 | |
CN104630221B (zh) | 抑制肿瘤细胞生长的shRNA及其重组载体与应用 | |
CN105233303B (zh) | 一种通过基因改造血管内皮细胞促进创面愈合的方法及其应用 | |
IL303378A (en) | vector | |
CN111925983A (zh) | 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Zhenzhou Inventor after: Tang Hao Inventor before: Chen Zhenzhou Inventor before: Tang Hao |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190520 Address after: 510200 Unit 201, Second Floor, No. 5 Spiral Fourth Road, Guangzhou International Biological Island, Guangdong Province Applicant after: Guangzhou Sai Biotechnology Co., Ltd. Address before: 510280 Department of Neurosurgery, Pearl River Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, Guangdong Province Applicant before: Chen Zhenzhou |
|
GR01 | Patent grant | ||
GR01 | Patent grant |